Abstract:
Background: Haematopoietic stem cell transplantation (HSCT) is the standard consolidation therapy for a variety of malignant and non-malignant diseases in children and adults. Our experience of HSCT in 26 patients with various indications is shared in this article. Materials and Methods: This was a retrospective analysis of first 26 patients who had undergone autologous and allogeneic transplant at our center, with M:F=2.7:1. The mean age for autologous transplant was 45 years (range 23-57 years). The median follow-up period was 23 months 25 days (range 3 to 47 months). The data was obtained carefully from medical records of the BMT center. Indications for autologous HSCT were Multiple Myeloma (12 patients), Non- Hodgkin’s lymphoma (7 patients), Hodgkin’s lymphoma (4 patients). Allogeneic HSCT were for Acute Myeloid Leukaemia (3 patients). Results: The mean time for WBC engraftment was 12 days (range 9-19 days) and for platelet engraftment was 16 days (range 11-35 days) in our autologous transplant cases and for allogeneic transplant mean time for WBC engraftment was 12 days (range 11-15 days) and for platelet engraftment was 14 days (range 12-17 days). Irradiated blood components were given in the pre, peri and post-transplant period to maintain Hb>8 gm/dl and platelet count >20X10⁹/L. Mean single-donor platelet requirement was 4 units (range 1-7), and mean packed red cell requirement was 1.5 units (range 1-6). The post-transplant complications encountered were mucositis, infections and diarrhoea. Oral mucositis was the most common complications. Twenty three (88.46 %) out of our 26 HSCT patients had developed mucositis, among them grade 1 in 5 patients, grade 2 in 11 patients, and grade 3 in 7 patients. There were 21 (80.76 %) cases of febrile neutropenia. Out of 26 patients 13 (50.0 %) bacterial infection were documented with culture positivity. One (3.84 %) case of viral infection was documented. Major bacterial infections were culture positive with Pseudomonas, Escherichia coli and Klebsiella followed by other species like acinatobacter, burkholderia and coagulase negative staphylococcus. One case of Cytomegalovirus was noted with significant viral copies that required Ganciclovir. Average duration of hospital stay after autologous HSCT was 23 days (range of 14-54 days) and allogeneic HSCT was 35 days (range of 30-57 days). 19 out of our 23 autologous transplant patients were in complete remission and all 03 cases of allogeneic HSCT were in remission. Conclusion: We believe our center has made a remarkable progress within short period of time to develop both autologous and allogeneic HSCT and is comparable with nationally and internationally renowned HSCT centers in terms of standard, quality and safety of care, and the ultimate outcomes.

Keywords: Haemopoietic stem cell transplantation, Conditioning regimen, Engraftment.

Introduction:
Stem cell transplantation is a procedure that can restore marrow function for patients who have had severe marrow injury or abnormalities of the immune system. Marrow injury can occur because of primary marrow failure, destruction or replacement of marrow by disease, or intensive chemical or radiation exposure. HSCT has become the standard of care for many patients with
defined congenital or acquired disorders of the hematopoietic system or with chemo- radio- or, immuno-sensitive malignancies. The first ever successful transplant was performed by Dr. E. Donnall Thomas in late 1950s for which he was awarded Nobel Prize of Physiology or Medicine in 1990. In our country, the first successful bone marrow transplant was done in March 2014 on a case of Multiple myeloma in Dhaka Medical College. Presently few haematopoietic stem cell transplant centers have been established in our country. Combined Military Hospital (CMH), Dhaka is a tertiary care hospital playing the key role in health sector in our country. In CMH Dhaka, Bone marrow center was inaugurated in May 05, 2015 by the Honourable Prime Minister. First case (Multiple myeloma) of autologous stem cell transplantation was done in our center on Nov 22, 2016.

Materials and Methods:
This was a retrospective study. The data was obtained carefully from medical case records from the BMT center. The statistical analysis was done using SPSS version 21. In this study, 26 patients had undergone autologous and allogeneic stem cell transplantation with M: F = 2.7:1. The first case was taken from November 2016 while last one from August 2020. Out of 26 patients, 23 patients underwent autologous stem cell transplant with mean age 45 years (range 23-57 years), M:F ratio of 3.6:1. Allogeneic stem cell transplant was done in 03 cases. All cases were Acute Myeloid Leukaemia (AML) with M:F ratio = 1:2. The youngest patient was 23 years and eldest one was 40 years old. It is to be mentioned here that in our country the first allogeneic HSCT was done successfully in our center. The median follow-up period was 23 months 25 days with range from 3 to 47 months.

Indications
Indications for autologous HSCT were Multiple Myeloma (12 patients), Non-Hodgkin lymphoma (07 patients), Hodgkin lymphoma (04 patients). Allogeneic HSCT was done in patients with Acute Myeloid Leukaemia (AML) with M:F ratio = 1:2. The youngest patient was 23 years and eldest one was 40 years old. It is to be mentioned here that in our country the first allogeneic HSCT was done successfully in our center. The median follow-up period was 23 months 25 days with range from 3 to 47 months.

Stem cells Collection
Stem cells were collected from peripheral blood after mobilization therapy either with G-CSF alone or G-CSF with Plerixafor. Stem cells were taken in range from 3.34 to 6.24x10^6/kg CD34+ counts.

Conditioning regimens
All patients with Multiple Myeloma received High dose Melphalan as conditioning regimen, while BEAM and R-BEAM regimen were used for patient with lymphoma. Reduced intensity conditioning (RIC) Regimen Flu-Mel was used in patient with AML-intermediate risk and the other two received Flu-Bu as myeloablative conditioning regimen.

Post-transplant care
Patients were nourished by special and sterilized food and special diet according to each patient characteristics and needs. They were observed closely for complications. All patients were treated in completely isolated rooms during the pre-, peri- and post-transplant period. These were conventional High-Efficiency Particulate-Air (HEPA) filtered rooms.

Results
Engraftment
By definition, WBC engraftment is, when absolute neutrophil count>500/cumm for three consecutive days and the platelet engraftment is the platelet count >20,000/ cumm for three consecutive days without any external transfusion support. The mean time for WBC engraftment was 12 days (range: 9-19 days) and for platelet engraftment was 16 days (range: 11-35 days) in our autologous transplant cases and for allogeneic transplant mean time for WBC engraftment was 12 days (range: 9-19 days) and for platelet engraftment was 16 days (range: 11-35 days) in our autologous transplant cases and for allogeneic transplant mean time for WBC engraftment was 12 days (range: 11-15 days) and for platelet engraftment was 14 days (range: 12-17 days).

| Table-I |
| --- |
| Sex distribution (n=26) |
| Sex | Number | Percentage |
| Male | 19 | 73 |
| Female | 7 | 27 |

| Table-II |
| --- |
| Summary of transplant performed by type (Allo HSCT vs Auto HSCT) (n=26) |
| Type of transplant | Number | Percentage |
| Auto HSCT | 23 | 88 |
| Allo HSCT | 3 | 12 |
Table-III

| Indications of Auto HSCT (n=23) |
|-------------------------------|
| Indications             | Number | Percentage |
| Multiple myeloma         | 12     | 52         |
| Non-Hodgkin lymphoma     | 7      | 30         |
| Hodgkin lymphoma         | 4      | 17         |

Table-IV

| Baseline characteristics of Autologous HSCT (n=23) |
|-----------------------------------------------|
| Total Number                                  | 23    |
| Age (median)                                  | 45    |
| Gender (M:F)                                  | 3.6:1 |
| Indication:                                   |
| Multiple Myeloma                              | 12    |
| Non-Hodgkin Lymphoma                         | 07    |
| Hodgkin Lymphoma                              | 04    |

Table-V

| Baseline characteristics of Allogeneic HSCT (n=03) |
|--------------------------------------------------|
| Total Number                                     | 03    |
| Age (median)                                     | 30    |
| Gender (M:F)                                     | 1:2   |
| Indication:                                      |
| Acute Myeloid Leukaemia-Intermediate risk        | 01    |
| Acute Myeloid Leukaemia-Relapsed                 | 01    |
| Acute Myeloid Leukaemia-FLT3,ITD Positive        | 01    |
| (High risk)                                      |

Table-VI

| Outcome of Autologous HSCT (n=23) |
|-----------------------------------|
| Median engraftment day            | WBC: 12 days |
| Median post-transplant hospital stay | 23 days (14-54 days) |
| Total Patient                     | 23           |
| Complete remission                | 19           |
| Death during peri-transplant period | 01           |
| Post-transplant death             | 02           |
| Relapse but alive                 | 01           |
| Overall survival (median 2 years) | 95.65%       |
| Transplant related mortality (TRM)| 4.34%        |

Table-VII

| Outcome of Allogeneic HSCT (n=03) |
|-----------------------------------|
| Median engraftment day            | WBC: 12 days |
| Median post-transplant hospital stay | 35 days (30-57 days) |
| Complete remission                | 03           |
| Overall survival                   | 100%         |

Table-VIII

| Conditioning regimen used for Autologous HSCT |
|-----------------------------------------------|
| Conditioning regimen | Indications | Protocol |
|----------------------|-------------|----------|
| BEAM & R-Beam regimen| Hodgkin Lymphoma | Day-7: Rituximab 375 mg/m² |
|                      | Non-Hodgkin Lymphoma | Day-6: Carmustine (BCNU)(300 mg/m²), Days -5, -4, -3, -2:Etoposide (200 mg/m²) and Cytarabine (Ara-C) (400 mg/m²), Day -1: Melphalan (140 mg/m²/dose) |
|                      | Multiple     | Day -1: Melphalan 200 mg/m² |
|                      | Myeloma      | Day 0: Stem cell transplant |
| Melphalan regimen     |             | Day 0: Stem cell transplant |
### Table IX

| Conditioning regimen | Indication | Protocol |
|----------------------|------------|----------|
| Reduced intensity (Flu-Mel) | Acute Myeloid Leukaemia- (Intermediate risk) Remission after induction chemo | Days -6, -5, -4, -3, -2: Fludarabine 30 mg/m² Day -1: Melphalan 140 mg/m² Day 0: Stem cell transplant |
| Myeloablative (Flu-Bu) | AML- Relapsed | Fludarabine 30 mg/m² D-5 to D-2 Busulfan 3.2 mg/kg/day in divided dose D-5 to D-2 |
| Myeloablative (Flu-Bu) | AML- FLT3, ITD (High risk) | Fludarabine 30 mg/m² D-5 to D-2 Busulfan 3.2 mg/kg/day in divided dose D-5 to D-2 |

### Table X

| Antibiotics | Dose | Duration |
|-------------|------|----------|
| Cap Cefixime | 400 mg daily | After removal of CV line |
| Inj Fluconazole followed by Tab Fluconazole | 200 mg daily | Starts on day 0 till D+28 |
| Inj Acyclovir followed by oral Tab | 400 mg thrice daily | Starts on day 0 till D+90 |
| Tab Phenoxymethyl penicillin | 500 mg twice daily | Starts D+29 to D+90 |

### Table XI

| Antibiotics | Dose | Duration |
|-------------|------|----------|
| Cap Cefixime | 400 mg daily | After removal of CV line |
| Syp Posaconazol | 200 mg three times a day | Starts on day 6 to day 14 |
| Tab Fluconazole | 200 mg daily | Starts on day 15 till D+28 |
| Tab Acyclovir | 400 mg twice daily | Starts on day 0 till D+90 |
| Tab Phenoxymethyl penicillin | 500 mg twice daily | Starts D+29 to D+90 |

### Table XII

| Drugs | Dose | Duration |
|-------|------|----------|
| Inj Cyclosporin | 2.5 mg/kg/dose | From D-1 till oral |
| Cap Cyclosporin | 200 mg/day | After injectable form |
| Inj MTX | 10 mg/m² and 7 mg/m² | D+1, D+3, D+6, D+11 |
Transfusion support
Irradiated blood products were given in the post-transplant period to maintain Hb>8 gm/dl and platelet count >20X10^9/L. Mean single-donor platelet requirement was 4 (range 1-17), and mean packed red cell requirement was 1.5 (range 0-6).

Post-transplant Complications
The post-transplant complications encountered were mainly mucositis, infections and diarrhoea.

Oral Mucositis
Oral mucositis was the most common complications, 23 (88.46%) out of our 26 HSCT transplant patients had developed mucositis, among them grade 1 in 5 patients, grade 2 in 11 patients, and grade 3 in 7 patients. Grade 2 mucositis patients were managed with dietary modification, analgesics, Sodi-bi-carb mouth wash and oral care. Patients with grade 3 mucositis required some interventions like parental nutrition.

Infection
There were 21 (80.76%) cases of febrile neutropenia. Out of 26 patients 13 (50.0%) bacterial infection cases were documented with culture positivity. One viral (3.84%) case was documented. Major bacterial infections were by *Pseudomonas, Escherichia coli* and *Klebsiella* followed by other specieslike *acinatobacter, burkholderia* and *coagulase negative staphylococcus*. One incidence of *Cytomegalovirus* was noted with significant viral copies that required intravenous Ganciclovir.

Gastrointestinal Complications
These were 10 (38.46%) incidences of diarrhoea and 01 (3.84%) incidence of oral bleeding.
Duration of hospital stay after transplant

Average duration of hospital stay after autologous HSCT was 23 days with a range of 14-54 days and allogeneic HSCT was 35 days with a range of 30-57 days.

Outcomes

One patient who was a case of relapsed Diffuse Large B-cell lymphoma (DLBCL) with spinal mass and heavily pre-treated, died during Transplant procedure. He developed typhilitis and septicaemia and we could not revive him and ultimately died. The rest of all cases of both autologous and allogeneic HSCT came out with successfully in the course of pre and peri-transplant periods as well as during transplant procedure. Two patients died after transplantation, one was a case of Plasma cell leukaemia who died after 08 months of transplantation due to relapse and another one was Non-Hodgkin Lymphoma (NHL)-DLBCL died after 10 months of transplantation due to respiratory tract infection (Pneumonia), he reported lately to hospital, otherwise he could have been saved. 19 out of our 23 autologous transplant patients were in complete remission. One of the autologous transplant patients had disease relapse and in good response with salvage chemotherapy. All 03 cases of allogeneic HSCT were in remission state. 1st case is now without any drugs and other two are getting tapering dose of GVHD prophylaxis and clinically stable.

Discussion:

Stem cells have different proliferative properties and functions depending on their physical location or tissue compartment. Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages. Hematopoiesis is a continuous developmental process in which HSCs make specific cell fate decisions, producing the various blood lineages. Though HSCT has many side effects and consequences, like drug toxicities, graft-versus-host disease (GVHD) and complications of immunosuppressive drugs, it is still the only curative option for many malignant hematologic (i.e. Refractory/relapsed leukaemia and lymphoma), non-malignant hematologic (i.e. severe aplastic anaemia, thalassaemia major), solid organ malignancies (i.e. seminoma, neuroblastoma) and genetic diseases (i.e. congenital immunodeficiency disease, inherited metabolic disorder). HSCs for transplantation can be collected from bone marrow or peripheral blood. Instead of bone marrow aspiration and biopsy which are invasive procedures, peripheral blood is a feasible and easily available source now-a-days. Because of using this new source of stem cells other than bone alone, “Hematopoietic stem cell transplantation” term has completely replaced the term “Bone Marrow Transplantation”. Our bone marrow/stem-cell transplant center is a new set-up compared to some other set-ups in this sub-continent and across the world. The first successful autologous transplant was performed on November 22, 2016 in a patient with Multiple myeloma and the first was performed on August 27, 2018 on a twenty-three year-old male with Acute Myeloid Leukaemia allogeneic transplant. Within 4 years period, a total of 26 patients had undergone HSCT at our center. Out of which, autologous HSCT was done in 23 patients and allogeneic HSCT in 03 patients. Haemopoietic stem cells were collected from peripheral blood following G-CSF and/or Plerixafor mobilization. The median age of autologous HSCT was 45 years in our study with range of 23 -57 years, whereas in the study of Mukhopadhyay A et al. the median age of the patients was 19.6 years, with a range of 5 years 8 months to 52 years. In Chirag AS et al. study the median age of autologous patients was 30 years. Mean duration of neutrophil engraftment was 12 days (9 -19 days) and platelet engraftment was 16 days (11-35 days) days in our patients for autologous HSCT which is consistent with the literature. For Allogeneic HSCT mean duration of neutrophilis engraftment was 12 days (11-15 days) and platelet engraftment was 14 days (12-17 days) which is comparable to other series. In our center febrile neutropenia developed in 21(80.76%) patients. Out of 26 patients, bacterial infection documented in 13 (50.0%) patients and viral infection in 01 (3.84%) patient. Infection rates were similar to other centers of this subcontinent but much higher than western studies where bacterial infection rate of 5%, viral infection rate of 7%, and fungal infection rate of 12%. The possible risk factors of infections in our center might be aggressive myeloablative conditioning regimens leading to prolonged neutropenia during pre-engraftment period. Environmental factors may also contribute to infection. Major complications during HSCT were infections, mucositis, disease-related complications, chemotherapy-induced complications and complications related to...
other co-morbidities. Major causes of mortality in our autologous HSCT patients were infections (66.66%) and disease relapse/progression (33.33%). Overall survival of our autologous HSCT patients was 95.65%. After a median follow up of 24 months (3-49 months), 82% of our autologous patients were in complete remission. Similar findings were noted in the study of Jasuja SK et al. where overall survival of autologous transplant patients was 100% and after a median follow up of 24 months (4-84 months), 84% of autologous patients were in complete remission. All three allogeneic HSCT cases were in remission state and overall survival is 100% in our study. By definition, complete remission means disappearance of all signs of cancer in response to treatment and does not always mean that the cancer has been cured. In a developing country like Bangladesh, there are very few centers which perform regular HSCT. This study will help in sharing its outcomes with other haematology/oncology practitioners and will encourage other centers to start stem-cell transplantation as standard of care for many otherwise incurable haemopoietic diseases.

**Conclusion:**

HSCT has become the treatment of choice in various haematological and non-haematological diseases. Nowadays HSCT is an accepted standard therapeutic option with different conditions and needs are increasing worldwide despite evolving targeted and immune therapies. Availability of resources, a network of specialists from all fields, good infrastructure, governmental support and access for patients to a transplant team is necessary for successful outcome of HSCT. Our center has made a remarkable progress pertaining to HSCT and is able to produce similar results and outcomes with nationally and internationally renowned HSCT centers in terms of quality of care, safety, and HSCT outcomes and we believe this will help us getting international accreditations such as JACIE EBMT.

**References:**

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813–1826.
2. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357(15):1472–1475.
3. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006; 37(5):439–449.
4. http://www.fredhutch.org/en/treatment/longtermfollowup/FAQstransplantation.html. Retrieved on 10 January 2021
5. Mafrua A, Mohiuddin AK, Albert CY, Spitzer TR, Ferdous J. et al. The journey of stem cell transplantation in Bangladesh: a hike to the state of the art with collaboration between DMCH and MGH. Blood Adv 2017; 1(Suppl 1): 62-64
6. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue- specific stem cell. Am J Pathol. 2006;169:338–346.
7. Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med. 2005;56:509– 538.
8. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81:2844–2853.
9. Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N, et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia.2003; 17(5):941-59.
10. Ogawa K, Noji H, Furukawa M, Harada-Shirado K, Mashimo Y, Takahashi H, et al. Hematopoietic stem cell transplantation in the Department of Hematology, Fukushima Medical University. Fukushima J MedSci.2010; 56(2):107-14.
11. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: A Global Perspective. JAMA2010;303(16):1617- 24.
12. Suárez-Álvarez B, López-Vázquez A, López-Larrea C. Mobilization and Homing of Hematopoietic Stem Cells. Stem Cell Transplantation. 2012;741:152-170.
13. Sánchez-Guijo FM, Orfao A, DelCañizo MC. Bone marrow transplantation extends its scope. AdvExpMedBiol. 2012;741:121-34.
14. Mukhopadhyay A, Gupta P, Basak J. Stemcelltransplantation: an experience from Eastern India. Indian Journal of Medical and Paediatric Oncology.2012;33(4):203-209.
15. Chirag AS, Karanwal A, Desai M, Pandya M, Shah R, et al. Hematopoieticstem-cell transplantation in the developing world: Experience from a center in western India. J Oncol.2015; 2015: 710543.
16. http://bethematch.org/For-Patients-and-Families/Getting-a-transplant/Engraftment-Days-0-30/. Retrieved on 12 January 2021
17. Sandeep Kj, Hooda L, Kasana RK, Hardayal, Meena H. Autologous hematopoietic stem cell transplant: a single center experience. 2017;6 (7):4830-4833.
18. NCI Dictionary of Cancer Terms. (n.d.), http://www.cancer.gov/dictionary?cdrid=45651